NAMS (NewAmsterdam Pharma Co NV) EV-to-EBIT : -5.12 (As of May. 18, 2025)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NewAmsterdam Pharma Co NV's Enterprise Value is $1,311.58 Mil. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-255.94 Mil. Therefore, NewAmsterdam Pharma Co NV's EV-to-EBIT for today is -5.12.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's EV-to-EBIT or its related term are showing as below:

NAMS' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.8 Med: -6.61 Max: -3.7
Current: -5.12

During the past 5 years, the highest EV-to-EBIT of NewAmsterdam Pharma Co NV was -3.70. The lowest was -32.80. And the median was -6.61.

NAMS's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 7.825 vs NAMS: -5.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NewAmsterdam Pharma Co NV's Enterprise Value for the quarter that ended in Mar. 2025 was $1,488.01 Mil. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-255.94 Mil. NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -17.20%.

NewAmsterdam Pharma Co NV EV-to-EBIT Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EV-to-EBIT Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

-18.86

-3.28

-8.04

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial								-8.47	-6.30	-6.09	-8.04	-5.81

Competitive Comparison of NewAmsterdam Pharma Co NV's EV-to-EBIT

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

NewAmsterdam Pharma Co NV EV-to-EBIT Calculation

NewAmsterdam Pharma Co NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1311.582	/	-255.935
	=	-5.12

NewAmsterdam Pharma Co NV's current Enterprise Value is $1,311.58 Mil.
NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-255.94 Mil.

NewAmsterdam Pharma Co NV (NAS:NAMS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	-255.935	/	1488.01143
	=	-17.20 %

NewAmsterdam Pharma Co NV's Enterprise Value for the quarter that ended in Mar. 2025 was $1,488.01 Mil.
NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-255.94 Mil.

NewAmsterdam Pharma Co NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.